-transparent.png){kind=logo}
Cetiedil, a drug reported to relieve painful crises in sickle cell anemia, has direct antisickling properties in vitro. However, neither oxygen affinity nor the solubility of deoxyhemoglobin S is altered by cetiedil. Due to the great influence the concentration of hemoglobin S has on the kinetics of gelation, we hypothesized that cetiedil might inhibit sickling by modifying erythrocyte Na+ or K+ movements in a manner which would prevent a rise in the concentration of intracellular hemoglobin. Cetiedil has two such effects: It causes a rise in passive Na+ movements and it inhibits a specific increase in K+ permeability secondary to a rise in cytoplasmic Ca2+ concentration. Cetiedil then may represent an alternate type of antisickling agent, exerting its effect through changes in erythrocyte membrane cation permeability rather than directly modifying hemoglobin S.
L R Berkowitz, and
E P Orringer
November 1990,
The American journal of physiology,
L R Berkowitz, and
E P Orringer
April 1986,
Science (New York, N.Y.),
L R Berkowitz, and
E P Orringer
April 2005,
The international journal of biochemistry & cell biology,
L R Berkowitz, and
E P Orringer
November 1991,
Journal of pharmaceutical sciences,
L R Berkowitz, and
E P Orringer
March 1990,
Blood,
L R Berkowitz, and
E P Orringer
April 1974,
The Journal of laboratory and clinical medicine,
L R Berkowitz, and
E P Orringer
February 1955,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
L R Berkowitz, and
E P Orringer
April 1975,
Prostaglandins,
L R Berkowitz, and
E P Orringer
January 1982,
Blood cells,
L R Berkowitz, and
E P Orringer
January 1984,
Acta haematologica,
